Company

Prazer Therapeutics

Biotechnology Research Kr 18 employees

Employees: 18
Contacts: 1
Emails: 1
Phones: 1

www.prazertx.com LinkedIn Crunchbase

Prazer Therapeutics Overview

Headquarters: Kr
Website: www.prazertx.com
Industry: Biotechnology Research
Employees: 18
Founded: 2019
Funding: 19.7M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Targeted Protein Degradation Small Molecule Inhibitor Drug Development

About Prazer Therapeutics

Prazer Therapeutics is a biotechnology company pioneering innovative therapeutics for various intractable diseases using rational drug design and next-generation targeted protein degradation (TPD) platform called SPiDEM. Our SPiDEM-based drug candidates for neurodegenerative diseases, cancers and inflammatory diseases have demonstrated superior pharmacokinetics and efficacy as well as reduced drug resistance compared to currently available TPD technologies. Our pipeline also encompasses anti-viral therapeutics to treat chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) as well as acute lung inflammation caused by coronaviruses, influenza viruses and respiratory syncytial virus (RSV).

Prazer Therapeutics Contact Details

People in AeroLeads: 4
With contact data: 1
Email contacts: 1; 25.0% coverage
Phone contacts: 1; 25.0% coverage

Prazer Therapeutics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Jiwoong Chun	Life Science Investor, Rph, Msc, 상무	South Korea, Korea, Republic of	View
Heejin Kim	Business Development Lead - U.s. Patent		View
Chan-Ki Min	Prazer Therpeutics		View
Wei Wu, Phd	Biotech Executive / Healthcare Investor	San Francisco Bay Area, United States	Email Phone